Lemtrada 'Behaves Like Chemotherapy For MS' Suggests 5-Year Efficacy Data
This article was originally published in Scrip
Executive Summary
Around two thirds of patients on Genzyme's multiple sclerosis treatment Lemtrada (alemtuzumab) need no additional treatment up to four years after the two courses of infusion that make up its standard treatment schedule, according to Genzyme's Mike Panzara, therapeutic area head of MS, neurology and ophthalmology.